Novartis Pharma AG: Novartis remibrutinib delivered comprehensive disease control in Phase III RMS trials, with proven, robust safety profile

Remibrutinib achieved significant and clinically meaningful reduction in relapses vs. teriflunomide, to approximately 1 relapse every 13 years, without the need for chronic B-cell depletion¹?²MRI d...
This is a short summary. The full story is published by Finanznachrichten.de.
Read full story at Finanznachrichten.de


